Skip to content
Menu

Orchestra BioMed Holdings, Inc. OBIO

Full chart Compare
Set alert

Price alert · OBIO

All alert types
7.00 USD -0.46 (-6.17%)

Regular-session close

7.00 0.00 0.00%

After hours · Nov 19, 4:01 PM ET

6.96 Day range 7.63
3.49 52-week range 7.46
YTD
+68.67%
1 year
+50.21%

5D +1.51 (+25.38%)

67ThuFriMonTueWed7.46
Market cap
550.93M
Revenue (ttm)
2.65M
EPS (ttm)
-0.70
Shares out
37.82M
Forward P/E
-2.66
YTD return
+68.67%
1-year return
+50.21%
50-day average
5.55
Volume
479.80K
Avg volume
411.63K
Open
7.50
Previous close
7.46
Day's range
6.96 – 7.63
52-week range
3.49 – 7.46
Beta
0.41
Price target
15.60 (+122.9%)

Key statistics

200-day average
5.90
Enterprise value
121.94M
Price / sales
67.35
Price / book
3.85
Revenue growth
135.60%
Free cash flow
-24.41M
Total cash
66.93M
Total debt
1.84M
Return on equity
-91.66%
Short % of float
3.63%

Fundamental scorecard

8 of 25 checks passed on OBIO’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
OBIO Revenue — quarterly 91.00K
OBIO Net income — quarterly -18.75M
OBIO EPS — quarterly -0.30

Earnings

OBIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.44-0.41+0.03+6.82%
Aug 12, 2024Jun 1, 2024-0.41-0.45-0.04-9.76%
Aug 12, 2024Jun 1, 2024-0.41———
May 13, 2024Mar 1, 2024-0.40———
May 13, 2024Mar 1, 2024-0.40-0.38+0.02+5.00%
Mar 27, 2024Dec 1, 2023-0.38———

Upgrades / downgrades

OBIO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 15, 2024HC Wainwright & Co.reitBuyBuy
Nov 13, 2024Chardan CapitalmainBuyBuy
Aug 22, 2024HC Wainwright & Co.init—Buy
Jul 25, 2024B. Riley Securitiesinit—Buy
Jun 12, 2024Chardan CapitalreitBuyBuy
Mar 28, 2024Chardan CapitalmainBuyBuy

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on OBIO — it syncs with the Stock Master app.

Insider holders

OBIO insider holders
InsiderRelationLatest transactionDateShares held
ARYEH JASON MDirectorStock Award(Grant)Jun 19, 202468,360
CONNEALY PAMELA ANNDirectorStock Award(Grant)Jun 19, 202421,289
FAIN ERIC SDirectorSaleSep 9, 20240
HOCHMAN DAVID PChief Executive OfficerPurchaseDec 17, 2024919,640
LITTLE WILLIAM REEDOfficerPurchaseMay 29, 2024307,859
MIKA YUVALOfficerStock Award(Grant)May 7, 2024158,905

Institution ownership

OBIO institution ownership
Holder% heldSharesValueReported
RTW Investments LP21.59%8,206,15938.49MSep 29, 2024
Perceptive Advisors Llc12.08%4,592,55621.54MSep 29, 2024
Blackrock Inc.5.11%1,942,3919.11MSep 29, 2024
Vanguard Group Inc3.45%1,309,8036.14MSep 29, 2024
Geode Capital Management, LLC1.49%567,2192.66MSep 29, 2024
Price (T.Rowe) Associates Inc1.35%512,6632.40MSep 29, 2024

Fund ownership

OBIO fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.84%698,1403.27MSep 29, 2024
iShares Russell 2000 ETF1.37%520,4242.44MOct 30, 2024
Vanguard Extended Market Index Fund1.09%414,5911.94MSep 29, 2024
Price (T.Rowe) Health Sciences Fund0.91%344,9851.62MSep 29, 2024
Blackrock Funds-Health Sciences Opportunity Portfolio0.69%262,3081.23MAug 30, 2024
Fidelity Small Cap Index Fund0.63%237,9561.12MAug 30, 2024